Investment
Features
FeesSafety
Academy
More
Pluang+

Kevin O’Leary predicts Bitcoin could peak at $150,000 amid growing institutional interest and regulatory clarity.

Market News
18 Sep 2026
Crypto Briefing
View Source
Bullish
Kevin O’Leary predicts Bitcoin could peak at $150,000 amid growing institutional interest and regulatory clarity.

Kevin O’Leary, once a Bitcoin skeptic, announced he is actively investing in digital assets again and expects Bitcoin to reach a peak price of $150,000 as regulatory clarity improves. He believes Bitcoin could capture 1% to 3% of institutional alternative-asset portfolios, potentially expanding its market value significantly. O’Leary highlighted the importance of major stock exchanges adopting blockchain technology as a key catalyst for broader institutional adoption. However, he emphasized that regulatory uncertainty remains the biggest hurdle for large-scale crypto investments, with progress dependent on clearer legislation. He is also investing in crypto-related energy infrastructure rather than just tokens, signaling a broader approach to the sector's growth.

Bitcoin price projections by Kevin O'Leary come as 46 of 50 major cryptocurrencies on Pluang rose today. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 18, 2026 17:54 WIB: SUSHI (SushiSwap) rose 12.84% to Rp4.420 with 83% sell order activity, DOT (Polkadot) gained 12.51% to Rp20.341 with 75% buy order activity, and SAND (The Sandbox) increased 11.37% to Rp681 with 60% buy order activity.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App